A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

Pharmaceutical companies are heading toward a steep patent cliff that could strip more than $230 billion in US drug sales ...

The U.S. Food and Drug Administration (FDA) on Thursday published more than 200 complete response letters ((CRLs)), through ...

As pressure builds around drug pricing and access, US trade group PhRMA is pushing back against criticism of pharmaceutical ...

David Newman December 27, 2024 05:54 am. Increased transparency is needed in all steps during the life of a patent in order to fulfill the Constitutional call for a marketplace of IP.

How the US Patent Office Could Change Under Trump The nomination of Howard Lutnick, chairman and CEO of financial services firm Cantor Fitzgerald, as Commerce Secretary signals a new chapter for ...

The story “Beware elected leaders who would weaken patents,” by Daniel M. Skovronsky The response. Daniel Skovronsky’s defense of the current patent system overlooks its fundamental flaws ...

Patent litigation reform could accelerate US biosimilar market entry, which lags behind the EU due to protracted legal processes. Biosimilar manufacturers face options like pre-clearance, ...

The patents being voluntarily disavowed are EP2800811, granted in 2017, and EP3401400, granted in 2019. Jenkins added the Nobelists still share one issued CRISPR patent in Europe, EP3597749, and ...

Blockchain and Web3 platform HUMBL has been issued a patent for its proprietary blockchain payments system from the United States Patent and Trademark Office.